Erin G Schuetz

List of Publications by Year
in descending order

47 papers	4,809 citations	218381 26 h-index	264894 42 g-index
49 all docs	49 docs citations	49 times ranked	5193 citing authors

#	Article	IF	Citations
1	Functional characterization of novel rare CYP2A6 variants and potential implications for clinical outcomes. Clinical and Translational Science, 2022, 15, 204-220.	1.5	8
2	Metabolomic and transcriptomic analysis reveals endogenous substrates and metabolic adaptation in rats lacking Abcg2 and Abcb1a transporters. PLoS ONE, 2021, 16, e0253852.	1.1	6
3	Genetic effects on liver chromatin accessibility identify disease regulatory variants. American Journal of Human Genetics, 2021, 108, 1169-1189.	2.6	22
4	Characterization of CYP3A pharmacogenetic variation in American Indian and Alaska Native communities, targeting CYP3A4*1G allele function. Clinical and Translational Science, 2021, 14, 1292-1302.	1.5	7
5	Vitamin D levels do not cause vitamin-drug interactions with dexamethasone or dasatinib in mice. PLoS ONE, 2021, 16, e0258579.	1.1	0
6	Interrogation of <scp>CYP</scp>2D6 Structural Variant Alleles Improves the Correlation Between <scp>CYP</scp>2D6 Genotype and <scp>CYP</scp>2D6â€Mediated Metabolic Activity. Clinical and Translational Science, 2020, 13, 147-156.	1.5	42
7	A New Liver Expression Quantitative Trait Locus Map From 1,183 Individuals Provides Evidence for Novel Expression Quantitative Trait Loci of Drug Response, Metabolic, and Sexâ€Biased Phenotypes. Clinical Pharmacology and Therapeutics, 2020, 107, 1383-1393.	2.3	20
8	Role of Vitamins A and D in BCR-ABL Arfâ˜'/â˜' Acute Lymphoblastic Leukemia. Scientific Reports, 2020, 10, 2359.	1.6	8
9	Beyond Competitive Inhibition: Regulation of ABC Transporters by Kinases and Protein-Protein Interactions as Potential Mechanisms of Drug-Drug Interactions. Drug Metabolism and Disposition, 2018, 46, 567-580.	1.7	49
10	Ketamine Pharmacokinetics and Pharmacodynamics Are Altered by P-Glycoprotein and Breast Cancer Resistance Protein Efflux Transporters in Mice. Drug Metabolism and Disposition, 2018, 46, 1014-1022.	1.7	23
11	Hepatic Abundance and Activity of Androgen- and Drug-Metabolizing Enzyme UGT2B17 Are Associated with Genotype, Age, and Sex. Drug Metabolism and Disposition, 2018, 46, 888-896.	1.7	42
12	Polymorphic Human Sulfotransferase 2A1 Mediates the Formation of 25-Hydroxyvitamin D₃-3-O-Sulfate, a Major Circulating Vitamin D Metabolite in Humans. Drug Metabolism and Disposition, 2018, 46, 367-379.	1.7	41
13	Novel CYP2A6 diplotypes identified through next-generation sequencing are associated with in-vitro and in-vivo nicotine metabolism. Pharmacogenetics and Genomics, 2018, 28, 7-16.	0.7	20
14	Zebrafish abcb11b mutant reveals strategies to restore bile excretion impaired by bile salt export pump deficiency. Hepatology, 2018, 67, 1531-1545.	3.6	38
15	Pheophorbide A: Fluorescent Bcrp Substrate to Measure Oral Drug-Drug Interactions in Real-Time In Vivo. Drug Metabolism and Disposition, 2018, 46, 1725-1733.	1.7	11
16	Genetic and Nongenetic Factors Associated with Protein Abundance of Flavin-Containing Monooxygenase 3 in Human Liver. Journal of Pharmacology and Experimental Therapeutics, 2017, 363, 265-274.	1.3	43
17	SUGP1 is a novel regulator of cholesterol metabolism. Human Molecular Genetics, 2016, 25, ddw151.	1.4	18
18	Expression Patterns of Organic Anion Transporting Polypeptides 1B1 and 1B3 Protein in Human Pediatric Liver. Drug Metabolism and Disposition, 2016, 44, 999-1004.	1.7	22

#	Article	IF	Citations
19	Interindividual Variability in Cytochrome P450-Mediated Drug Metabolism. Drug Metabolism and Disposition, 2016, 44, 343-351.	1.7	131
20	Serine 350 of human pregnane X receptor is crucial for its heterodimerization with retinoid X receptor alpha and transactivation of target genes in vitro and in vivo. Biochemical Pharmacology, 2015, 96, 357-368.	2.0	24
21	TheCYP2C19Intron 2 Branch Point SNP is the Ancestral Polymorphism Contributing to the Poor Metabolizer Phenotype in Livers withCYP2C19*35andCYP2C19*2Alleles. Drug Metabolism and Disposition, 2015, 43, 1226-1235.	1.7	23
22	In Vivo Imaging of Human MDR1 Transcription in the Brain and Spine of MDR1-Luciferase Reporter Mice. Drug Metabolism and Disposition, 2015, 43, 1646-1654.	1.7	10
23	Regulation of Coagulation Factor XI Expression by MicroRNAs in the Human Liver. PLoS ONE, 2014, 9, e111713.	1.1	34
24	Intestinal CYP3A4 and midazolam disposition in vivo associate with VDR polymorphisms and show seasonal variation. Biochemical Pharmacology, 2012, 84, 104-112.	2.0	48
25	Role of SLC10A1 SNPs in regulating cytochrome P450 expression. FASEB Journal, 2012, 26, 784.6.	0.2	0
26	Dysregulation of intestinal CYP3A4â€dependent 1,25â€dihydroxyvitamin D3 catabolism: a potential mechanism for drugâ€induced osteomalacia. FASEB Journal, 2008, 22, 1135.3.	0.2	0
27	MDR1 genotype is associated with hepatic cytochrome P450 3A4 basal and induction phenotype. Clinical Pharmacology and Therapeutics, 2006, 79, 325-338.	2.3	91
28	Steroid and xenobiotic receptor and vitamin D receptor crosstalk mediates CYP24 expression and drug-induced osteomalacia. Journal of Clinical Investigation, 2006, 116, 1703-1712.	3.9	215
29	Lessons from the CYP3A4 Promoter. Molecular Pharmacology, 2004, 65, 279-281.	1.0	42
30	PXR (NR1I2): splice variants in human tissues, including brain, and identification of neurosteroids and nicotine as PXR activators. Toxicology and Applied Pharmacology, 2004, 199, 251-265.	1.3	186
31	Structural Determinants of P-Glycoprotein-Mediated Transport of Glucocorticoids. Pharmaceutical Research, 2003, 20, 1794-1803.	1.7	112
32	Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine. Pharmacogenetics and Genomics, 2003, 13, 19-28.	5.7	264
33	Development of A Real-Time in Vivo Transcription Assay: Application Reveals Pregnane X Receptor-Mediated Induction of CYP3A4 by Cancer Chemotherapeutic Agents. Molecular Pharmacology, 2002, 62, 439-445.	1.0	51
34	Transcriptional Control of Intestinal Cytochrome P-4503A by 1Î±,25-Dihydroxy Vitamin D₃. Molecular Pharmacology, 2001, 60, 1399-1406.	1.0	316
35	Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nature Genetics, 2001, 27, 383-391.	9.4	1,954
36	Mdr1b facilitates p53-mediated cell death and p53 is required for Mdr1b upregulation in vivo. Oncogene, 2001, 20, 303-313.	2.6	17

#	Article	IF	Citations
37	Induction of Cytochromes P450. Current Drug Metabolism, 2001, 2, 139-147.	0.7	53
38	Creation of polarized cells coexpressing CYP3A4, NADPH cytochrome P450 reductase and MDR1/P-glycoprotein. Pharmaceutical Research, 2000, 17, 803-810.	1.7	33
39	THE HUMAN CYP3A SUBFAMILY: PRACTICAL CONSIDERATIONS*. Drug Metabolism Reviews, 2000, 32, 339-361.	1.5	209
40	Drug disposition as determined by the interplay between drug-transporting and drug-metabolizing systems. , 1999, 13, 219-222.		30
41	Environmental Xenobiotics and the Antihormones Cyproterone Acetate and Spironolactone Use the Nuclear Hormone Pregnenolone X Receptor to Activate the CYP3A23 Hormone Response Element. Molecular Pharmacology, 1998, 54, 1113-1117.	1.0	143
42	Phenotypic variability in induction of p-glycoprotein mrna by aromatic hydrocarbons in primary human hepatocytes. Molecular Carcinogenesis, 1995, 12, 61-65.	1.3	49
43	Induction of P-Glycorprotein mRNA by protein synthesis inhibition is not controlled by a transcriptional repressor protein in rat and human liver cells. Journal of Cellular Physiology, 1995, 165, 261-272.	2.0	17
44	Regulation of human liver cytochromes P-450 in family 3A in primary and continuous culture of human hepatocytes. Hepatology, 1993, 18, 1254-1262.	3.6	176
45	Regulation of human liver cytochromes P-450 in family 3A in primary and continuous culture of human hepatocytes. Hepatology, 1993, 18, 1254-1262.	3.6	28
46	Regulation of cytochrome P-450p by phenobarbital and phenobarbital-like inducers in adult rat hepatocytes in primary monolayer culture and in vivo. Biochemistry, 1986, 25, 1124-1133.	1.2	130
47	Genetic Variants of Xenobiotic Receptors and their Implications in Drug Metabolism and Pharmacogenetics. , 0, , 241-273.		3